Financial Data and Key Metrics Changes - System wide sales increased to $129.6 million, up 2.6% compared to Q2 2024 [10] - Comp sales for clinics open for at least 13 months rose by 1.4% for the quarter [10] - Revenue from continuing operations grew by 5% to $13.3 million [23] - Consolidated adjusted EBITDA reached $3.2 million, a 52% increase compared to Q2 2024 [10][25] - Unrestricted cash and equivalents as of June 30, 2025, were $30 million [11] Business Line Data and Key Metrics Changes - The company refranchised 37 clinics, reducing corporate clinics from 13% to 8% of the portfolio [12] - The refranchising included the sale of 31 corporate clinics in Arizona and New Mexico for $11.1 million [12] - The company opened 7 franchise clinics and closed 6 during the quarter [22] Market Data and Key Metrics Changes - The company noted macroeconomic headwinds affecting new patient counts, impacting overall performance [14] - The focus on pain relief messaging is expected to attract more patients, as 80% of new patients cite pain as their reason for visiting [15][56] Company Strategy and Development Direction - The company aims to become a pure play franchisor and is pursuing "The Joint 2.0" strategy to enhance profitability and patient experience [9] - Initiatives include a shift in marketing focus from general wellness to pain relief, enhancing digital marketing, and optimizing pricing strategies [9][15] - The company plans to explore additional revenue streams and new markets in the future [28][80] Management's Comments on Operating Environment and Future Outlook - Management acknowledged softer sales trends and macroeconomic challenges but expressed confidence in addressing these through marketing and pricing strategies [27][39] - The company revised its 2025 guidance for system wide sales to a range of $530 million to $550 million, down from previous estimates [27] - Management emphasized the importance of brand awareness and targeted marketing to improve patient acquisition [15][56] Other Important Information - The company plans to continue its stock repurchase program, authorizing up to $5 million through June 2027 [26] - Two new directors were added to the board, enhancing governance and strategic oversight [30] Q&A Session Summary Question: Details on the lowered comp guide - Management noted recent trends showed softness mainly in new patient counts, despite improved conversion rates and consistent attrition [36][39] Question: Impact of pricing increases - Management confirmed ongoing dynamic revenue management strategies, including smaller, more frequent price increases to maintain affordability [43][73] Question: Breakdown of EBITDA guidance - Management typically does not split guidance between continuing and discontinued operations but noted ongoing efforts to manage G&A expenses [45][46] Question: Effect of recent clinic sales on back office expenses - Management indicated potential reductions in G&A expenses as clinics transition to franchise operations, with long-term savings expected [70][71] Question: Exploration of additional products and services - Management is committed to exploring incremental products and services related to pain management while maintaining operational simplicity [78][80]

Financial Data and Key Metrics Changes - System wide sales for Q1 2025 were $132.6 million, up 5% compared to Q1 2024, indicating resilience in the current economic environment [10] - Revenue from continuing operations increased by 7% to $13.1 million compared to $12.2 million in Q1 2024 [29] - Adjusted EBITDA from continuing operations was $46,000, a significant decrease from $425,000 in Q1 2024 [10][29] - Net loss from continuing operations was $506,000, compared to a loss of $399,000 in Q1 2024 [30] Business Line Data and Key Metrics Changes - Comp sales for all clinics open for at least 13 months were up 3% for Q1 2025 and increased to 4% in March 2025 [10][24] - Comp sales for mature clinics (open for at least 48 months) were down 2% [24][82] - The company refranchised two corporate clinics and opened five franchise clinics during Q1 2025, with a total of 969 clinics, of which 847 (87%) are franchise clinics [25][26] Market Data and Key Metrics Changes - The company expects system wide sales for 2025 to be between $550 million and $570 million, compared to $530.3 million in 2024 [32] - Comp sales for clinics open for 13 months or more are expected to be in the mid-single digits for 2025 [32] Company Strategy and Development Direction - The company aims to become a pure play franchisor, with 93% of corporate clinics under Letters of Intent (LOIs) for refranchising [12][51] - The strategy includes dynamic revenue management, strengthening digital marketing, and enhancing patient-facing technology [12][19][22] - The company is focusing on pain-centric messaging to attract new patients, as 74% of new patients cite pain as a reason for visiting [35][39] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a dynamic consumer environment and is closely monitoring the situation while pushing ahead with the transition plan [11] - The company anticipates a transformative financial impact as clinics shift from company-owned to franchise clinics, leading to increased franchise royalties and fees [34] - Economic headwinds, inflation, and volatile consumer sentiment are expected to impact the beginning of 2025, but the company remains optimistic about future profitability [34] Other Important Information - The company has welcomed new executives to enhance legal strategy and operations, aiming to improve clinic quality and economics [41] - The Joint has been recognized as one of the fastest-growing franchises and ranked in the Franchise 500 [41] Q&A Session Summary Question: New patient ad metrics and retention trends - Management noted that new patient volumes have been affected by overall consumer sentiment, but retention rates remain stable [44][46] Question: Metrics on profitability and overhead reduction - Management is not ready to provide specific metrics but expects profitability to improve as G&A expenses are reduced [47][49] Question: Timeline for refranchising process completion - Management intends to exit 2025 as a pure play franchisor and hopes to accelerate the refranchising process [51] Question: Comp sales performance and dynamics - Management did not disclose April comp sales but confirmed a return to 4% in March [57] - Franchise clinic comp performance mirrors consolidated comp, with corporate clinic comp trailing slightly [59] Question: Dynamic pricing opportunities - Management is exploring various pricing models, with potential for double-digit impacts on system wide sales [61] Question: Selling and marketing expenses normalization - Management expects selling and marketing expenses to normalize by Q3 2025 after a dual agency transition [68] Question: Strategies for mature clinics to improve comp sales - Management is implementing operational strategies and marketing tactics aimed at strengthening existing clinics [83][85]

Financial Data and Key Metrics Changes - Total company revenue for Q1 2025 was $180 million, an increase of $26 million or 17% compared to Q1 2024 [19] - Adjusted EBITDA increased by 39% to $30 million, with margins improving by 260 basis points [7][20] - Net income improved by $5.2 million to $1 million, with income available to stockholders roughly breakeven at $0.00 per diluted share [23] Business Line Data and Key Metrics Changes - Lindblad segment revenues were $131 million, an increase of $13 million or 11% compared to the prior year [20] - Land experiences revenues were $49 million, an increase of $13 million or 38% compared to Q1 2024, driven by increased trips and higher revenue per guest [20] - Net yields increased by 25% to $1,521, the highest quarterly net yield in the company's history [7][20] Market Data and Key Metrics Changes - Occupancy increased by 13 percentage points from 76% to 89% compared to the prior year [20] - Bookings for 2025 and 2026 are tracking ahead of the prior year in both segments [7][35] Company Strategy and Development Direction - The company focuses on maximizing revenue generation, optimizing financial performance, and exploring accretive growth opportunities [9] - Strategic initiatives include a partnership with Disney and international expansion efforts, particularly in the UK [12][14] - The company aims to enhance financial transparency and has introduced net yield expectations for 2025, expecting growth of 7% to 10% [15][26] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the demand for experiential travel despite economic volatility [8] - The company is closely monitoring the macroeconomic environment and has seen fluctuations in bookings, particularly in April [35] - Future guidance reaffirms total company tour revenue between $700 million and $750 million for the year [26] Other Important Information - The company completed the purchase of two expedition vessels, enhancing its fleet [19] - A new dynamic pricing strategy has been implemented to better manage pricing based on demand [41] - The company is committed to sustainability and community impact through various initiatives [16][18] Q&A Session Summary Question: What drove the strong occupancy in the quarter? - Management indicated that the strong occupancy was due to a combination of expanded audience from the Disney partnership, charter businesses, and a stronger revenue management strategy [31] Question: How has the current booking environment been affected by macroeconomic factors? - Management noted that bookings for 2025 and 2026 remain ahead of the prior year, but April bookings were less consistent [35] Question: What is the status of dynamic pricing implementation? - Management confirmed that dynamic pricing has been initiated and is expected to enhance flexibility in pricing based on demand [41] Question: How is the company performing in terms of the Antarctica program? - Management reported that the Antarctica program is performing extremely well, with high demand and nearly sold out for 2026 [44]

Financial Data and Key Metrics Changes - Total company revenue for Q1 2025 was $180 million, an increase of $26 million or 17% compared to Q1 2024 [18] - Adjusted EBITDA increased by $8.4 million or 39% year-over-year, reaching $30 million [19] - Net income improved by $5.2 million to $1 million, with income available to stockholders approximately breakeven at $0.00 per diluted share [22] Business Line Data and Key Metrics Changes - Lindblad segment revenues were $131 million, an increase of $13 million or 11% compared to the prior year [19] - Land experiences revenues were $49 million, an increase of $13 million or 38% compared to Q1 2024, driven by increased trips and the acquisition of Wyneland Thompson Adventures [19] - Occupancy increased by 13 percentage points from 76% to 89%, with net yield per available guest night increasing by 25% to $1,521, the highest in company history [19][6] Market Data and Key Metrics Changes - Bookings for 2025 and 2026 are tracking ahead of the prior year in both segments, indicating strong demand despite macroeconomic challenges [6][34] - The company is seeing positive momentum in bookings, particularly in the last couple of weeks, although April bookings were less consistent [34] Company Strategy and Development Direction - The company focuses on three strategic pillars: maximizing revenue generation, optimizing financial performance, and exploring accretive growth opportunities [8] - The company is enhancing its financial transparency practices and introducing net yield expectations for 2025, expecting a growth of 7% to 10% [14][25] - The company is committed to sustainability, which is central to its mission, and is actively involved in community initiatives [15][16] Management's Comments on Operating Environment and Future Outlook - Management remains cautiously optimistic about the future, with bookings for 2025 and 2026 ahead of prior year levels [34] - The company acknowledges the complex macroeconomic environment but believes it is well-positioned due to its focus on experiential travel for high-income demographics [7][34] Other Important Information - The company completed the purchase of two expedition vessels, enhancing its fleet capacity [18] - The company is expanding its international presence, particularly in the UK, to tap into the growing adventure travel market [11] Q&A Session Summary Question: What drove the strong occupancy in the quarter? - Management indicated that the strong occupancy was due to a combination of expanded audience from the Disney partnership, charter businesses, and a stronger revenue management strategy [30] Question: How has the current booking environment been affected by macroeconomic factors? - Management noted that while April bookings were less consistent, there has been positive momentum in recent weeks, and bookings for 2025 and 2026 remain ahead of prior year [34] Question: How did capacity adjustments impact yields? - Management explained that lower capacity due to drydocks allowed for higher occupancy growth, supported by demand generation activities [38] Question: What is the status of dynamic pricing implementation? - Management confirmed that dynamic pricing strategies have been initiated, allowing for more flexible pricing based on demand [40] Question: How is the fly cruise program performing? - Management reported that the fly cruise program is in high demand and is practically sold out for 2026, with increased capacity planned for 2027 [43]